Trial reportThe ISME journal2014
Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection.
Trial report in The ISME journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 175 citations in OpenAlex.
- The Role of Microbiota and Fecal Transplantation in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2026Pooled it
- Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review.Nutrients · 2019Pooled it
- Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial.World journal of gastroenterology · 2023Trial
- Trial
- Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions inGut microbes · 2025Article
- Fecal microbiota transplantation as a therapeutic modality for recurrentAnnals of medicine and surgery (2012) · 2025Review
- Comparison of the gastrointestinal bacterial microbiota between dairy cows with and without mastitis.Frontiers in microbiology · 2024Article
- Vowst's FDA approval is a boon for the prevention of recurrentAnnals of medicine and surgery (2012) · 2023Article
- Is there a role for microbiome-based approach in common variable immunodeficiency?Clinical and experimental medicine · 2023Review
- Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention ofMicroorganisms · 2023Review
- Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection.Cell host & microbe · 2023Review
- Leveraging microbiome rediversification for the ecological rescue of soil function.Environmental microbiome · 2023Article
- Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.Frontiers in microbiology · 2023Review
- A High-Carbohydrate Diet Prolongs Dysbiosis and Clostridioides difficile Carriage and Increases Delayed Mortality in a Hamster Model of Infection.Microbiology spectrum · 2022Article
- Fomite Transmission Follows Invasion Ecology Principles.mSystems · 2022Article
- Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome.International journal of molecular sciences · 2022Article
- Soil salinization accelerates microbiome stabilization in iterative selections for plant performance.The New phytologist · 2022Article
- Effect of antibiotics in the first week of life on faecal microbiota development.Archives of disease in childhood. Fetal and neonatal edition · 2022Article
- Article
- Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen.Microorganisms · 2021Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent Clostridium difficile infection (CDI) can be effectively treated by infusion of a healthy donor faeces suspension. However, it is unclear what factors determine treatment efficacy. By using a phylogenetic microarray platform, we assessed composition, diversity and dynamics of faecal microbiota before, after and during follow-up of the transplantation from a healthy donor to different patients, to elucidate the mechanism of action of faecal infusion. Global composition and network analysis of the microbiota was performed in faecal samples from nine patients with recurrent CDI. Analyses were performed before and after duodenal donor faeces infusion, and during a follow-up of 10 weeks. The microbiota data were compared with that of the healthy donors. All patients successfully recovered. Their intestinal microbiota changed from a low-diversity diseased state, dominated by Proteobacteria and Bacilli, to a more diverse ecosystem resembling that of healthy donors, dominated by Bacteroidetes and Clostridium groups, including butyrate-producing bacteria. We identified specific multi-species networks and signature microbial groups that were either depleted or restored as a result of the treatment. The changes persisted over time. Comprehensive and deep analyses of the microbiota of patients before and after treatment exposed a therapeutic reset from a diseased state towards a healthy profile. The identification of microbial groups that constitute a niche for C. difficile overgrowth, as well as those driving the reinstallation of a healthy intestinal microbiota, could contribute to the development of biomarkers predicting recurrence and treatment outcome, identifying an optimal microbiota composition that could lead to targeted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.